The Prevalence and Association of Cognitive Impairment with Sleep Disturbances in Patients with Chronic Liver Disease

• Published in: Brain sciences Vol. 12; no. 4; p. 444
• Main Authors: Plotogea, Oana-Mihaela, Diaconu, Camelia Cristina, Gheorghe, Gina, Stan-Ilie, Madalina, Badea, Mircea-Alexandru, Prelipcean, Cristina Cijevschi, Constantinescu, Gabriel
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.03.2022; MDPI
• Subjects: actigraphy; Alcohol; chronic liver disease; Cirrhosis; Cognitive ability; cognitive impairment; Encephalopathy; Hepatic encephalopathy; Hepatitis; Hospitals; Lactulose; Liver cirrhosis; Liver diseases; Patients; psychometric testing; Quality of life; Quantitative psychology; Questionnaires; Sleep; Sleep and wakefulness; Sleep disorders; Statistical analysis; United States > US; Romania; chronic liver disease; sleep disorders; actigraphy; cognitive impairment; psychometric testing
• ISSN: 2076-3425; 2076-3425
• DOI: 10.3390/brainsci12040444

Introduction/Aim. The aim of this study was to assess the prevalence of cognitive impairments and their association with sleep patterns in a cohort of patients diagnosed with chronic liver disease (CLD). Material and methods. The present paper is a prospective cohort study, carried out over a period of 12 months, among patients with various stages of CLD. We evaluated the cognitive function through psychometric hepatic encephalopathy score (PHES), while sleep was assessed by actigraphy and two self-reported questionnaires: Epworth Sleepiness Scale (ESS) and Pittsburgh Sleep Quality Index (PSQI). Results. Seventy-four patients with CLD were considered eligible and were enrolled between December 2020−November 2021. The prevalence of minimal hepatic encephalopathy (MHE) in the entire cohort was 41.9%, and the diagnosis was considered for PHES scores ≤ −3. Patients with cirrhosis recorded significantly lower PHES scores compared to patients with other CLDs but without cirrhosis (−3.19 ± 3.89 vs. 0.19 ± 2.92, p < 0.05). Patients who exhibited MHE suffered from poor sleep, daytime somnolence, disturbed nighttime sleep, and low overall sleep efficacy. Patients diagnosed with MHE and undergoing treatment with lactulose and/or rifaximin for prevention of overt hepatic encephalopathy (HE) showed better results in terms of sleep parameters compared to patients diagnosed with MHE but without treatment. Conclusions. This research increases awareness regarding the connection between sleep features and MHE in patients with cirrhosis and other CLDs. A deeper insight into the subclinical stages of HE and associated sleep disturbances is warranted in future studies.